AU2002219218A1 - Method for screening for progesterone receptor isoform-specific ligands - Google Patents

Method for screening for progesterone receptor isoform-specific ligands

Info

Publication number
AU2002219218A1
AU2002219218A1 AU2002219218A AU2002219218A AU2002219218A1 AU 2002219218 A1 AU2002219218 A1 AU 2002219218A1 AU 2002219218 A AU2002219218 A AU 2002219218A AU 2002219218 A AU2002219218 A AU 2002219218A AU 2002219218 A1 AU2002219218 A1 AU 2002219218A1
Authority
AU
Australia
Prior art keywords
screening
progesterone receptor
specific ligands
receptor isoform
isoform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002219218A
Inventor
Ulrike Fuhrmann
Christa Hegele-Hartung
Michael Klotzbucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of AU2002219218A1 publication Critical patent/AU2002219218A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
AU2002219218A 2000-12-28 2001-12-21 Method for screening for progesterone receptor isoform-specific ligands Abandoned AU2002219218A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US25831200P 2000-12-28 2000-12-28
US60/258,312 2000-12-28
US30587501P 2001-07-18 2001-07-18
US60/305,875 2001-07-18
PCT/EP2001/015200 WO2002054064A2 (en) 2000-12-28 2001-12-21 Method for screening for progesterone receptor isoform-specific ligands

Publications (1)

Publication Number Publication Date
AU2002219218A1 true AU2002219218A1 (en) 2002-07-16

Family

ID=26946565

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002219218A Abandoned AU2002219218A1 (en) 2000-12-28 2001-12-21 Method for screening for progesterone receptor isoform-specific ligands

Country Status (8)

Country Link
EP (1) EP1373888A2 (en)
JP (1) JP2004516841A (en)
AR (1) AR032050A1 (en)
AU (1) AU2002219218A1 (en)
NO (1) NO20032969L (en)
PE (1) PE20020784A1 (en)
UY (1) UY27107A1 (en)
WO (1) WO2002054064A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL164032A0 (en) * 2002-03-11 2005-12-18 Schering Ag 5-ä2-Hydroxy-3-'1-(3-trifluoromethylphenyl)-cyclopropyl-propionylaminoü-phtalide and related compounds with progesteronepeceptor
DE102007049630A1 (en) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy
DE102007023614A1 (en) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula
DE102007032800A1 (en) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
DE102007058747A1 (en) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nonsteroidal progesterone receptor modulators
EP2070909A1 (en) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Non-steroidal progesterone receptor modulators
CN113801889B (en) * 2021-09-18 2023-04-07 中国农业科学院农业质量标准与检测技术研究所 Cell screening model, construction method and application thereof, saccharomycete, preparation method and application thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8617653D0 (en) * 1986-07-18 1986-08-28 Ici Plc Amide derivatives
DE4235220A1 (en) * 1992-10-13 1994-06-16 Schering Ag Gestagen effective 19,11ß-bridged 4-estrene
DE4337416A1 (en) * 1993-10-27 1995-05-04 Schering Ag 10,11beta-C¶2¶-bridged steroids
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
DE4413185A1 (en) * 1994-04-12 1995-10-19 Schering Ag 11beta, 19-bridged 13alpha alkyl steroids
DE19723722A1 (en) * 1997-05-30 1998-12-10 Schering Ag Nonsteroidal progestogens

Also Published As

Publication number Publication date
NO20032969D0 (en) 2003-06-27
NO20032969L (en) 2003-08-28
WO2002054064A2 (en) 2002-07-11
JP2004516841A (en) 2004-06-10
WO2002054064A3 (en) 2003-10-16
AR032050A1 (en) 2003-10-22
UY27107A1 (en) 2002-03-22
PE20020784A1 (en) 2002-10-03
EP1373888A2 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
AU1199600A (en) Estrogen receptor ligands
EP0939531A3 (en) Method for forming an icon
AU2002323098A1 (en) Selective estrogen receptor modulators
AU5572399A (en) Integrated document development method
AU1055001A (en) Method for immobilizing material
EP1469316A2 (en) Screening method
AU7433900A (en) Screening methods
AU3840499A (en) Device for making detachable tube-joint
AU2702999A (en) Method for producing bags
AU2002219218A1 (en) Method for screening for progesterone receptor isoform-specific ligands
AU7904500A (en) Method for the screening of alpha2delta-1 subunit binding ligands
AU5099299A (en) Methods for determining cross-hybridization
AU5671699A (en) Grp receptor ligands
AU1553101A (en) Screening method
AU6429000A (en) Screening method
AU4605099A (en) Method for detecting infection-phase-specific antibodies
AU1177899A (en) Screening for analytes using labeled receptors
AU1583600A (en) Method for measuring non-transferrin bound iron
AU2872501A (en) Screening method
AU3034799A (en) Method for producing stanols
AU2310900A (en) Screening methods
GB9908676D0 (en) Method for screening compounds
AU3686800A (en) Screening apparatus
AU5436499A (en) Assay method for cardiovascular disease
AU4856501A (en) Screening method for compounds

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase